Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence

The body's internal clock runs on proteins that switch genes on and off across a 24-hour cycle. One of these, REV-ERB, does double duty: it also governs how cells manage fat and energy. Cancer cells are unusually hungry, rewiring their metabolism to fuel rapid growth — which raised an intriguing question: what if REV-ERB were deliberately turned up rather than left to its normal rhythm?

We tested drug-like molecules that activate REV-ERB against a wide range of cancer types, including brain tumors, leukemia, and cancers of the breast, bowel, and skin. Across the board, the cancer cells died. In mice with glioblastoma — an aggressive and typically deadly brain cancer — the REV-ERB drug shrank tumors faster and extended survival compared to mice treated with the standard glioblastoma drug. The mechanism appears twofold: the drugs cut off cancer cells' ability to make and store the fats they depend on, and they block autophagy, the recycling process cells use to survive stress.

The same compound also killed a type of senescent cells, which are worn out cells that stop dividing but refuse to die and are thought to drive a good deal of inflammation.

This is early-stage laboratory work, not a treatment — no patient has been cured by it. But it makes an important point: the body clock isn't just a schedule to respect for better health, it's a druggable target in its own right. That reframing opens up a line of cancer research that simply didn't exist before.